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A B S T R A C T
This presentation highlights strengths and weaknesses of cervical cytology screening in Croatia, with particular ref-
erence to the opportunistic screening, the use of conventional Papanicolaou (Pap) test and the analysis of some organiza-
tional, educational and performance issues that are associated with it. Its aim is to propose measures to improve the effi-
cacy of cervical cytology screening in order to reduce cervical cancer mortality. Currently, in excess of 450,000 Pap tests/
year are examined at 35 laboratories scattered throughout the country. All of these laboratories use standard operating
procedures including internal and external quality control. They employ a total of 68 cytologists and 91 cytotechno-
logists. The sensitivity of cervical screening in Croatia is 90.0%, specificity 98.6%, positive predictive value 92.3%, nega-
tive predictive value 98.1% and overall diagnostic accuracy 97.2%. The high diagnostic accuracy of cervical cytology is
attributed to the long-standing tradition of education and training of cytologists (postgraduate MSc course since 1967,
independent residency since 1974) and cytotechnologists (since 1968). This tradition spanning more than half a century
means that today in Croatia there is a developed network of cytology laboratories staffed by highly competent cytologists
and trained cytotechnologists. The high accuracy of cancer detection through Pap tests provides strong evidence in sup-
port of cervical cytology screening remaining the basic method of prevention for cervical carcinoma. However, some modi-
fications to the current situation are needed. These relate primarily to opportunistic screening. The current screening
coverage rate is 68%, although there is capacity, which would allow for all women at risk, i.e. those aged 25–64, to be
screened once in three years. The screening coverage relates mainly to those women visiting gynecological out patient
clinics for unrelated conditions. A properly organized and controlled national screening programme should replace this.
This should be accompanied by the introduction of alternative, highly sensitive methods of sample collection and prepa-
ration, such as are available through the introduction of new technologies, e.g. liquid based cytology.
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Introduction
Cytological diagnosis of conventional cervicovaginal
smear or Pap test is one of the most efficient screening
tests known to date, which has been credited with the
significant decline in the incidence and mortality of uter-
ine carcinoma all over the world. In Croatia, it has been
used as the main method of secondary prevention of
uterine carcinoma for more than half a century now, be-
ing at the same time employed as a classic screening test
for lesion detection and as a differential diagnosis me-
thod predicting histological diagnosis. The rate of cervical
carcinoma in Croatia, directly resulting from the large-
scale use of Pap test, reflects the indisputable value of
the method, while also pointing to some shortcomings.
The current state of cervical cytology in Croatia is
presented. In addition to its achievement, the aim was to
identify the weaknesses, such as opportunistic screening,
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the use of conventional Pap test and analysis of the orga-
nizational, educational and performance issues with the
aim to propose measures to upgrade the efficacy of cervi-
cal screening.
The History of Gynecological Cytology
in Croatia
In Croatia, as in the rest of Europe, gynecologists
were the first to perform microscopic analysis of cervical
cytological specimens. The first laboratory headed by E.
Bar{i}, a gynecologist, was established in 1953 at Univer-
sity Department of Gynecology, School of Medicine, Uni-
versity of Zagreb, now University Department of Gyne-
cology and Obstetrics, Zagreb University Hospital Center.
Jasna Ivi}, MD was the first to devote exclusively to
gynecological cytology since 1959. In 1968, she was ap-
pointed Head of the Laboratory of Cytology, which devel-
oped into Institute of Gynecological Cytology in 1984;
Jasna Ivi} organized cytology service in line with the
principles adopted worldwide, and is most credited for
the progress of cervical cytology in Croatia1–3. During the
past fifty years, Institute of Gynecological Cytology in
collaboration with other institutions, Department of Cy-
tology and Clinical Genetics, University Department of
Gynecology and Obstetrics, Merkur University Hospital
in particular, has stimulated continuous development of
gynecological cytology in the professional, scientific and
educational aspects in Croatia, while promoting due rec-
ognition of the Croatian gynecological cytology abroad.
At the beginning of the third millennium, these efforts
have also been intensified at Department of Gyneco-
logical Cytology, University Department of Gynecology
and Obstetrics, Rijeka University Hospital Center and
Department of Clinical Cytology, Osijek University Hos-
pital, which also became the leading laboratories in the
field in Croatia.
The key events in the development of clinical cytology
in Croatia are mentioned in Table 1, for which merit goes
to many professionals1, amongst others: Professor Ante
Zimolo, Professor Erik Hauptmann, Professor Inga ^re-
pinko, and already mentioned Professor Jasna Ivi}.
Specialist Education of Cytologists
and Cytotechnologists
The 1967–1974 period characterized by the establish-
ment of organized education of cytotechnologists (con-
tinuing education course for cytotechnologists in 1968)
and cytologists (Postgraduate Study in Medical Cytology
in 1967 and respective residency in 1974, both subse-
quently renamed as Clinical Cytology). Both played a key
role in the development of diagnostic as well as gyneco-
logic cytology in Croatia.
The Postgraduate Study in Medical Cytology was es-
tablished at the Zagreb University School of Medicine in
1967, with 31 courses attended by 397 postgraduate stu-
dents held until 2006. The study underwent two revi-
sions, first in 1996 with the introduction of professional
studies, and second in 2005 as residency study.
In 1974, independent residency in Medical Cytology,
subsequently renamed as Clinical Cytology, was intro-
duced. Initially, residency took three years (pathology
one year and cytology two years, with postgraduate study
as a form of organized education). Twenty years later, it
grew into four-year residency (pathology one year and
cytology three years, also with two terms of postgraduate
study), within the frame of general revision of residency
curricula in Croatia. The introduction of independent
residency resulted in appropriate education of these pro-
fessionals, qualified to meet the very demanding chal-
lenges posed by the profession.
In the process of approaching the European Union,
the phase of adjustment of education in clinical morphol-
ogy professions of cytology, pathology and forensic medi-
cine has begun, resulting in a new proposal of residency
in all three until now independent professions.
The education of cytotechnologists is an important
part of education in cytology. Professor Inga ^repinko or-
ganized the first course of additional education of medical
technicians for cytology technicians. During the 1968–
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Postgraduate Study in Medical Cytology, later Clinical Cytology at the School of Medicine of the University of Zagreb
Continuing education course for cytotechnologists at the Medical College of Zagreb
Section of Cytology and Cytological Diagnosis established at the Croatian Medical Association (CMA), to be later
renamed as the Croatian Society of Clinical Cytology of the CMA
Later, continuing education courses for the cytologists, cytology technicians, gynecologists, etc., organized by
the Croatian Society of Clinical Cytology of the CMA and Zagreb University School of Medicine
Residency in Medical Cytology, later Clinical Cytology, as independent residency regulated by the Ministry of Health
and Social Welfare of the Republic of Croatia
Fifth grade qualification – laboratory technician at the Medical College, Zagreb
Continuing education for cytotechnologists at the Ministry of Health and Social Welfare of the Republic of Croatia
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1977 period, the education of cytotechnologists was per-
formed in the form of six-month course upon completion
of medical technician high school education at Medical
College in Zagreb. One-year programme in the form of
fifth grade education was offered from 1981 to 1992 at
the same College; however, the status of thus trained
professionals was not properly solved. The pursuit for
continuing, complete and officially recognized education
led to the development of two-year programme, initially
delivered at the Medical College. The program was veri-
fied by the Medical College and the School of Medicine
(at the time, College was part of the School of Medicine);
however, it has not yet been performed in practice.
Since 2000, sixty cytotechnologists have received edu-
cation at three courses organized by the Ministry of
Health and Social Welfare of the Republic of Croatia, in
collaboration with the Croatian Society of Clinical Cytol-
ogy of the Croatian Medical Association (CMA), and held
by Assist. Professor @eljka Znidar~i}, having thus at least
in part mitigated the worrying shortage of these ex-
tremely important team members.
The one-year course consisted of 630 periods of practi-
cal and theoretical education in all fields of cytology diag-
nosis with 200 periods of education in particular cytology
services. Adjustment to the Bologna Process has opened
new options for cytotechnologists at the Medical College;
harmonization of the new form and curriculum of their
education has just been under way.
Current Organization, Medical Staff
and Number of Cytological Analyses
Presentation of the current structure in terms of orga-
nization, staff profile and number of Pap tests performed
is based on a survey performed by the Croatian Society of
Clinical Cytology of the CMA in 2003 and 2005.
According to the above survey, gynecological cytology
is performed at 35 of 48 (73%) organizational units.
Twenty-seven of these are at state-owned health institu-
tions (25 at hospitals and 2 at health centres) and eight
in private offices (6 specialist practices and 2 at private
polyclinics). Of the twenty-five hospital units, eight are
organized as independent departments and seventeen
are combined with other professions, i.e. fourteen within
pathology, two at the University Departments of Gyne-
cology and Obstetrics, and one at the Department of Lab-
oratory Diagnosis. Eight cytology laboratories are pre-
dominantly engaged in gynecological cytology, whereas
the remaining 27 laboratories are equally dealing with
general diagnostic by cytology and gynecologic cytology.
Two private cytology laboratories were excluded from
analysis because their heads failed to submit current
data, and one hospital laboratory was excluded due to the
very low proportion of Pap tests in their overall perfor-
mance; thus, data on 32 units are presented (Figure 1).
Sixty-two professionals with university education
(not including residents), i.e. 58 clinical cytologists, two
pathologists, one anaesthesiologist and one graduated bi-
ologist, along with 91 cytotechnologists, and 43 techni-
cal, administrative and auxiliary staff members are em-
ployed in 32 cytology laboratories. The cytologists to
cytotechnologist to other personnel ratio is 1:1.4:0.6. An
ideal screening team would consist of one cytologist, two
cytotechnologists and one laboratory technician; accord-
ingly, the majority of cytology teams in Croatia are in
part incomplete.
A total of 574,290 cervical smears were taken in 2005
in a whole country, of which 452,809 (79%) Pap tests
were successfully performed. The proportion of Pap tests
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Fig. 1. Number of Pap tests per cytologists/cytology team at 32 cytology units in Croatia in 2005.
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out of the total number of tests varied from 59% to 100%
in different counties. Forty-nine cytologists and seventy-
one cytotechnologists performed these Pap tests. Com-
parison of the number of Pap tests and number of cytolo-
gists and cytotechnologists engaged in their performance
showed that one cytologist with the respective team have
performed a mean of 9,241 Pap tests, whereas one cyto-
technologist examined a mean of 6,378 Pap smears (ap-
proximately 28 per day!). The laboratories included in
the analysis varied greatly according to the number of
tests performed, Pap test in particular (Figure 1). The
number of Pap tests per cytologists/cytology team ranged
from 2000 to 16,000, and per cytotechnologist from 3300
to 10,000.
The highly uneven pattern of performance recorded
in the cytology service across Croatia according to orga-
nizational unit and localization, number and profile of
professional staff, and number of tests per team per-
formed imposes the need of developing distinct legal reg-
ulations to standardize the mode of organization, loca-
tion, staff structure and performance standards in the
field of cytological diagnosis, consistent with the respec-
tive catchments population. Taking into account more
than 30 years of residency in clinical cytology, it is not
justifiable that cytology testing is performed by anyone
but physicians-cytologists.
Overall, the high number of specialists in cytology
and properly educated cytotechnologists, and the num-
ber of Pap tests performed (n=452,809) offer a capacity
adequate to cover the female population at risk aged
25–64, if screened once in three years. According to the
2001 census, there were 1,178,052 women of these age
groups in Croatia4; thus, screening per year should cover
392,684 women.
»Zagreb 2002« Uniform Classification
of Uterine Cervix Cytological Findings
in Croatia
In Croatia, a uniform classification named »Zagreb
2002«5, a modification of »Zagreb 1990«6 and »NCI Be-
thesda System 2001«7, has been used in cytological anal-
ysis of cervical smears. Two groups of »satisfactory« and
»unsatisfactory« (explaining the reason for the latter)
are used on assessment of specimen adequacy. According
to general classification, findings are categorized as »ne-
gative for intraepithelial or invasive lesion« (normal
finding, changes with reactive and reparatory reactions,
a finding suggesting certain risk) and »abnormal cells«
(cellular changes that are morphologically consistent with
intraepithelial or invasive malignant lesions).
Descriptive diagnosis includes the items »microorgan-
isms« (listing the microorganisms that can be identified
directly or based on the specific cytopathic effect), »other
non-neoplastic findings«, and »abnormal cells« (squa-
mous, glandular, of undetermined significance, and other
malignant neoplasms). The group of »other non-neoplastic
findings« that may be found with or without abnormal
cells includes reactive cell changes, reparatory epitheli-
um, spare cells, parakeratosis, dyskeratosis, hyperkera-
tosis, a post-hysterectomy finding of cylindrical cells, a
finding of endometrial cells beyond the cycle or in meno-
pause, and a conclusion that the cytohormonal status
does not correspond to the patient’s age and/or history.
Squamous lesions are divided into three groups, as
follows: »atypical squamous cells« (ASC), »squamous in-
traepithelial lesion« (SIL), and »squamous cell carcino-
ma«. The ASC group is further subdivided into »undeter-
mined significance« (ASC-US), »high-grade SIL cannot
be excluded« (ASC-H), and »invasion cannot be exclu-
ded«. Considering SIL group, all three terms currently in
use have been retained, with the addition of »invasion
cannot be excluded«. This parallel terminology (dyspla-
sia – CIS, cervical intraepithelial neoplasia – CIN and
SIL) has been retained to avoid diagnostic-therapeutic
identification of moderate dysplasia (CIN 2) with severe
dysplasia and carcinoma in situ (CIN 3), thus leaving an
opportunity for cytological and colposcopical follow- up
of the lesion up to its regression or progression.
Glandular lesions are also classified into three groups,
as follows: »atypical glandular cells« (three subgroups:
probably reactive, probably intraepithelial, and probably
invasive), »adenocarcinoma in situ« (AIS), and »adeno-
carcinoma«, with a note on its origin.
The groups of »abnormal cells of undetermined signif-
icance« and of »other malignant neoplasms« refer to ab-
normalities where differential cytological diagnosis can-
not be established.
This uniform classification enables both internal and
external quality control of the laboratory performance,
along with appropriate reproducibility of cervical cytol-
ogy relative to the terminology adopted in the world.
Methods of Quality Assurance in
Cervical Cytology
All laboratories have been structured in line with the
standard work protocols, to include internal and external
quality control8–11.
Internal quality control of laboratory performance in-
cludes the following:
a) control of material sampling,
b) control of technical processing (preparation) and smear
staining,
c) primary screening using the following methodology8,10:
• selected pre-screening – refers to pre-screening of
cervical smears in patients with particular clinical
entities such as abnormal bleeding, clinically sus-
pect cervix, etc. In this case, all slides should be ob-
served as having evidence for abnormality, i.e. they
should be examined twice by a cytotechnologist and
also by a cytologist if some abnormality has been
demonstrated;
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• double screening – it is a reliable method of internal
control, ensuring continuous caution on test perfor-
mance. It is used in all diagnostical specimens;
• proportional re-screening – so-called random scre-
ening of some 10% of negative specimens;
• rapid screening – it includes re-screening of all neg-
ative and inadequate smears by use of the known
rapid screening technique, performed by cytotech-
nologists that have not previously analyzed the re-
spective specimens12;
• previous cytology review – it is performed when
high-grade dyskaryosis/dysplasia is found in cyto-
logical specimen, and previous cytology was nega-
tive or has been inadequate for 5-years back, when
carcinoma or high-grade CIN is histopathologically
diagnosed following negative cytology, and when cy-
tological finding is negative following previous cyto-
logical abnormalities;
d) slides and findings are stored for at least 10 years;
e) result analysis by daily cyto-histological correlation of
findings; and
f) continuing education.
External quality control implies control of perfor-
mance of a number of cytology laboratories by a commis-
sion consisting of the representative profession and na-
tional health authorities. The commission controls the
work of a cytological laboratory and tests skill of the
cytotechnologists and/or cytologists either by mail or by
testing organized at a previously agreed location13. Prep-
aration exchange includes several (e.g., four or five) labo-
ratories, each submitting up to 10 slides sent from one to
another laboratory for screening. Eventually, they all
meet together to discuss their results. Verification tests
make an alternative method of external quality control,
where 10 slides are analyzed within 2 hours; all slides in-
cluded in cervical carcinoma screening can be analy-
zed8,10.
The Value of Opportunistic Screening
by Conventional Pap Test
The efficacy of conventional Pap test in opportunistic
screening is assessed on the basis of its detection and dif-
ferential diagnostic value, and population coverage. In
addition to accurate Pap test may also produce inaccu-
rate diagnosis, i.e. false negative or false positive results.
A false negative finding may be due to insufficient sam-
pling, inappropriate laboratory processing, screening
failure, or erroneous evaluation of the cells present in the
respective smear. A false positive cytology finding is by
definition a positive cytology finding in a woman free
from cervical lesion. It also includes erroneous interpre-
tation as well as so-called falsely false positive findings,
referring to a positive cytology finding in a patient with
cervical lesion but negative biopsy finding. The propor-
tion of cytological screening error can be defined as the
number of false negative findings in the total number of
cytology smears analyzed over a period of observation,
yielding a very low error rate, or as the number of false
negative findings in the total number of women with cer-
vical lesion, which yields a much greater error percent-
age. As about 95% of smears negative for CIN lesions, the
value of cytological screening lies in the possibility of de-
tecting those 5% of specimens that are abnormal; thus,
the error proportion may be expressed also as the number
of false negative findings out of the total number of wo-
men with cervical lesion. When thus expressed, the rate
of false negative findings varies from nil to 29.7%14–27.
The measures of cervical cytology appropriateness as
a screening test are its sensitivity, specificity, predictive
values, and diagnostic accuracy. In case of cervical cytol-
ogy, sensitivity is the rate of positive cytology findings in
a group of women with intraepithelial or invasive cervi-
cal lesion, ranging from 30 to 87%28. Specificity is the
rate of negative cytology findings in a group of women
free from intraepithelial or invasive cervical lesion, vary-
ing from 86 to 100%28. Sensitivity and specificity are not
independent measures. An increase in sensitivity with a
seemingly decreased rate of false negative findings may
be accompanied by an increase in the number of false
positive findings, and vice versa. The relationship be-
tween sensitivity and specificity is best illustrated by
predictive values.
Positive predictive value (PPV) is a measure of proba-
bility that an individual with positive finding is ill. In cer-
vical cytology, it is a useful measure of finding accuracy
in case of lesions that require additional diagnostic pro-
cedures. On determining PPV, the time to histologic veri-
fication should be limited to a maximum of six months. In
case of a longer period, the inconsistency between his-
tological and cytological diagnoses resulting in a low PPV
may be due to lesion regression rather than inaccurate
cytological finding. Negative predictive value (NPV) is a
measure of probability that an individual with negative
finding is healthy.
In a study conducted in Croatia to estimate the reli-
ability of conventional Pap smear in the screening for
both low and high grade intraepithelial cervical lesions
and early invasive cervical cancer29,30, the rate of false
negative findings was 10%, of which screening error ac-
counted for 3.1% and sampling error for the rest of 6.9%.
The rate of false positive findings was 1.4%, of which er-
roneous smear interpretation accounted for 0.6%, and SIL
detected on follow-up and/or repeat biopsy for the rest of
0.8%, switching the categorization of these cases from
»cytologically false positive« to »histologically false nega-
tive« due to error on collecting biopsy specimens. The
sensitivity was 90.0%, specificity 98.6%, PPV 92.3%,
NPV 98.1%, and overall diagnostic accuracy 97.2%.
The main objection to conventional cytology as a
screening test refers to its low sensitivity. However, the
rate of false negative findings can be considerably re-
duced by strictly following professional rules, primarily
careful sampling and smear preparation, fixation and
processing through thorough screening and professional
interpretation, thus upgrading the test sensitivity.
M. Pajtler et al.: Cervical Cytology Screening in Croatia, Coll. Antropol. 31 (2007) Suppl. 2: 47–54
51
U:\coll-antropolo\coll-antro-suppl-2-2007\08-pajtler.vp
3. travanj 2007 11:53:06
Color profile: Disabled
Composite  150 lpi at 45 degrees
Conventional Pap test is not only used as a classical
screening test for lesion detection but also as a differen-
tial diagnostic method predicting histological diagnosis.
It is of great importance because the type and severity of
the lesion detected will dictate further diagnostic and
therapeutic procedure. Differential cytology of squamous
intraepithelial lesions, distinguishing three grades of dys-
plasia and carcinoma in situ, has a total sensitivity of
67%, specificity of 87%, PPV of 59%, NPV of 90%, and
overall diagnostical accuracy of 75%; diagnostic accuracy
increases with lesion severity and is directly proportional
to reproducibility of each cytological diagnosis29,31–33.
The small number of glandular intraepithelial lesions
neoplasia relative to squamous ones, and the fact that
their morphological properties have only been inten-
sively investigated and characterized in the last two de-
cades, have resulted in the lack of experience and atten-
tion in the search for these lesions in cytological smears.
Consequentially, diagnostic accuracy in recognizing ab-
normal columnar cells in cytological smears, alone or in
combination with a squamous component, is only 55%33.
The Osijek-Baranja County was taken as a represen-
tative sample to assess the risk population coverage by
opportunistic screening4. Pap smears collected at gyne-
cology clinics and hospital departments in the County
were analyzed at Department of Clinical Cytology, Osijek
University Hospital in Osijek, Croatia. Dur- ing a three-
-year period (2003–2005), 104,062 conventional Pap smears,
77,692 (74.7%) of these primary cases and 26,370 (25.3%)
duplicate cases, were examined. The number of primary
cases corresponded to the total number of women exam-
ined. The target population of women aged 25–64, that
should be examined once in three years, accounted for
60,374 (68%) Pap smears (Table 2).
Opportunistic screening covered 68% of the target
population, i.e. those spontaneously visiting gynecolo-
gical offices for reproductive age physiology/pathology,
while the total number of tests performed should have
included the entire population at risk. Study results ex-
plained the unfavourable pattern observed in the inci-
dence and mortality of cervical carcinoma in Croatia as
compared with other west and south European coun-
tries, pointing to the need of implementing the national
programme of cancer prevention and early detection,
which should include the entire population at risk34.
Liquid-Based Cytology: Alternative
Cytology Method of Higher Sensitivity
New techniques of cervical-endocervical cytology sam-
pling and processing have been developed in the last few
decades, with the introduction of liquid-based cytology
(LBC) as one of the most important achievements in the
field. In contrast to conventional Pap test, in LBC tech-
nique the specimen obtained from uterine cervix is not
applied onto the slide but the instrument is immersed in
a glass containing transport fixation liquid, where it is
thoroughly vortexed for optimal utilization of the entire
cell material35. Using conventional method, up to 80% of
the specimen is lost with the discarded instrument36–38; it
is considered to be one of the main reasons for false nega-
tive Pap tests (6–50%)39–42 and false negative findings in
women with HGSIL and invasive carcinoma (20–50%)42–44.
Cell suspension in fixation liquid is stable at room
temperature for up to several weeks38,45, and is labora-
tory processed by use of semi-automated or automated
commercial devices. Currently, a number of such devices
are available, with those approved by the United States
Food and Drug Administration (FDA) for cervical screening
being best known: ThinPrep processors (Cytic Corpora-
tion, Massachusetts, USA) and AutoCyte-Prep system
(ThiPath Imaging, Inc., North Carolina, USA). Excess
blood and inflammatory exudate is mechanically remov-
ed from suspension specimen, and a small representative
specimen is transferred and uniformly applied in thin
layer onto the slide, in a circle of 13 mm (AutoCyte-
-Prep) or 19 mm (ThinPrep) in diameter.
Most authors point to the advantages of LBC over
conventional smear, which include a reduced rate of in-
adequate samples35,46–48 (by even up to 97%)47 and of
false negative findings49–51, higher rate of abnormal cyto-
logy findings detected52,53, and significantly shorter time
(by up to 60%) needed for analysis of a specimen pre-
pared by the new method48. Another advantage of the
LBC method, also admitted by those who found no differ-
ence when evaluating these two methods of cervical cy-
tology sample preparation54, refers to the fact that the re-
maining cell suspension can be used for more sophi-
sticated diagnostical methods such as Human papillo-
mavirus (HPV) analysis (so- called reflex testing), thus
upgrading the screening test sensitivity and specificity,
in order to prevent unnecessary overtreatment of lesions
that would otherwise undergo spontaneous regression.
In addition, cell suspension can also be used for the diag-
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TABLE 2
NUMBER OF WOMEN AGED 25–64 IN OSIJEK-BARANJA COUNTY (2001 CENSUS) AND NUMBER OF WOMEN COVERED BY CYTOLOGY




25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64
Osijek-Baranja County 10,378 11,188 12,396 12,635 12,045 10,730 9,195 10,655 89,222
With Pap test 10,081 9,180 8,922 9,124 8,761 6,908 4,288 3,110 60,374
% of tested 97 82 72 72 75 64 47 29 68
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nosis of other sexually transmitted diseases (Chlamydia
trachomatis, gonorrhea, etc.), or molecular and cyto-
genetical methods can be employed, thus making »the
impossible possible« in the future55. The more so, the
rest of material can be used for additional preparations
for education and external quality control.
The major hindrance to the introduction of LBC tech-
nique is the high cost of its utilization in organized
screening actions. Yet, according to the report issued by
the Sheffield School of Health and Related Research
(ScHARR)48, the initially high price of the instrumenta-
tion will pay off, primarily through a reduced number of
inadequate specimens, avoiding unnecessary retesting,
and centralization of material processing at only a few
laboratories. Furthermore, the implementation of LBC
requires additional training of cytologists and cytotech-
nologists. Cytological analysis of thick layers may fre-
quently prove quite demanding, along with a lower speci-
ficity as compared with conventional Pap test56.
Conclusion
The tradition of more than half a century, the net-
work of cytology laboratories staffed with cytologists and
properly trained cytotechnologists of enviable skill and
competence, and more than 450,000 Pap tests performed
per year provide strong basis for the success of cytologi-
cal screening as the basic method of secondary preven-
tion for cervical carcinoma in Croatia. Opportunistic
screening in Croatia reflected in the substantial decrease
of cervical cancer incidence from 26 to 15 per 100,000
women-years between 1970 and 1990 remaining almost
constant till then57. However, some modifications appear
to be necessary, which primarily refers to the substitu-
tion of opportunistic screening by a properly designed,
organized and controlled national screening, as all pre-
conditions for it have been fulfilled. In addition, alterna-
tive, high sensitivity methods of sample preparation
should be introduced in the cytology service at the na-
tional level.
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CITOLO[KI PROBIR RAKA VRATA MATERNICE U HRVATSKOJ
– PRO[LOST, SADA[NJOST I BUDU]NOST
S A @ E T A K
Prikazan je segment klini~ke citologije u Hrvatskoj koji se bavi cervikalnom citologijom, kako bi se analizom organi-
zacije, izobrazbe i u~injena rada, uz objektivnu vrijednost identificirale i slabe to~ke oportunisti~kog probira konvencio-
nalnim Papa-testom, te predlo`ile mjere za postizanje njegove najve}e mogu}e u~inkovitosti u cilju smanjena smrti od
raka vrata maternice. U 35 laboratorija koji su ustrojeni u skladu sa standardnim protokolom rada uz kontinuiranu
unutarnju i vanjsku kontrolu kvalitete, u kojima je uposleno 68 specijalista citologa i 91 educirani citoskriner, pregleda
se na godinu preko 450.000 Papa testova. Iako je tim brojem mogu}e jednom u tri godine obuhvatiti sve `ene u rizi~noj
dobi od 25–64 godine, obuhvati se tek 68% onih koje se spontano javljaju ginekologu zbog fiziologije/patologije repro-
duktivne dobi. U Hrvatskoj je pouzdanost citolo{kog probira na zavidnoj razini, {to se mo`e pripisati dugoj tradiciji
sustavne izobrazbe citologa (poslijediplomski studij od 1967. i samostalna specijalizacija od 1974.) i citoskrinera (od
1968.). Osjetljivost Papa-testa je 90,0%, specifi~nost 98,6%, pozitivna prediktivna vrijednost 92,3%, negativna predikti-
vna vrijednost 98,1%, a ukupna dijagnosti~ka to~nost 97,2%. Glavna zamjerka se odnosi na nisku osjetljivost. Tradicija
du`a od pola stolje}a, razvijena mre`a citolo{kih laboratorija sa zavidnim fondom specijalista citologa i educiranih cito-
tehnologa, te broj pregledanih Papa-testova na godinu sna`an su argument mi{ljenju da citolo{ki probir u Hrvatskoj
treba ostati temeljnom metodom sekundarne prevencije raka vrata maternice. Nu`ne su pritom odre|ene promjene, u
prvom redu zamjena oportunisti~kog probira dobro osmi{ljenim, organiziranim i kontroliranim nacionalnim probirom
za koji su ispunjeni svi preduvjeti, te uvo|enje alternativnih metoda pripreme uzorka vi{e osjetljivosti.
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